Online first
Letter to the Editor
Published online: 2024-11-05

open access

Page views 27
Article views/downloads 17
Get Citation

Connect on Social Media

Connect on Social Media

A cross-sectional study using the Surveillance, Epidemiology, and End Results Program database to estimate the prevalence of Myelodysplastic syndrome (MDS) in the United States

Shangyi Fu12, Michel Adeniran3, Zachrieh Alhaj3, Diana Bonilla3, Melissa Marchan-Martinez3, Ibeth Caceres1, Danny Huynh4

Abstract

Myelodysplastic syndrome (MDS) is a hematologic disorder characterized by ineffective blood cell production leading to cytopenias and a propensity for progression to acute myeloid leukemia (AML). In this study, we aimed to assess the prevalence of MDS in the United States population using data from the Surveillance, Epidemiology, and End Results (SEER) database. Our analysis revealed that the highest prevalence of MDS was observed in the over 85 age group, with an overall prevalence rate of 0.02%. Furthermore, our findings indicated that the White race had the highest prevalence rate compared to other racial groups. However, it should be noted that the SEER database, most likely due to sampling biases, has a potential underestimation of minority populations, but SEER and the US population are statistically similar enough for comparison. These results suggest a need for further research on the underlying factors contributing to the prevalence of MDS in the United States population; factors such as genetic, environmental, comorbidities, and racial disparities should be explored. Early diagnosis and treatment of MDS are crucial for improving outcomes for patients with this condition. 

Article available in PDF format

View PDF Download PDF file

References

  1. Hasserjian RP. Myelodysplastic Syndrome Updated. Pathobiology. 2019; 86(1): 7–13.
  2. Garcia-Manero G. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023; 98(8): 1307–1325.
  3. Gondek LP, DeZern AE. Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states. Lancet Haematol. 2020; 7(1): e73–e81.
  4. SEER Cancer Statistics Review, 1975–2018 [Internet]. https://seer.cancer.gov/csr/1975_2018/index.html (2023 Mar 2).
  5. Bureau UC. 2018 Population Estimates by Age, Sex, Race and Hispanic Origin [Internet]. https://www.census.gov/newsroom/press-kits/2019/detailed-estimates.html (2023 Mar 30).